Literature DB >> 10593883

MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway.

T H Chao1, M Hayashi, R I Tapping, Y Kato, J D Lee.   

Abstract

Big mitogen-activated protein (MAP) kinase (BMK1), also known as ERK5, is a member of the MAP kinase family whose cellular activity is elevated in response to growth factors, oxidative stress, and hyperosmolar conditions. Previous studies have identified MEK5 as a cellular kinase directly regulating BMK1 activity; however, signaling molecules that directly regulate MEK5 activity have not yet been defined. Through utilization of a yeast two-hybrid screen, we have identified MEKK3 as a molecule that physically interacts with MEK5. This interaction appears to take place in mammalian cells as evidenced by the fact that cellular MEK5 and MEKK3 co-immunoprecipitate. In addition, we show that a dominant active form of MEKK3 stimulates BMK1 activity through MEK5. Moreover, we demonstrate that MEKK3 activity is required for growth factor mediated cellular activation of endogenous BMK1. Taken together, these results identify MEKK3 as a kinase that regulates the activity of MEK5 and BMK1 during growth factor-induced cellular stimulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593883     DOI: 10.1074/jbc.274.51.36035

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling.

Authors:  M T Diaz-Meco; J Moscat
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation.

Authors:  G Pearson; J M English; M A White; M H Cobb
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

3.  Role of MEKK2-MEK5 in the regulation of TNF-alpha gene expression and MEKK2-MKK7 in the activation of c-Jun N-terminal kinase in mast cells.

Authors:  K Chayama; P J Papst; T P Garrington; J C Pratt; T Ishizuka; S Webb; S Ganiatsas; L I Zon; W Sun; G L Johnson; E W Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

Authors:  Matthew S Squires; Paula M Nixon; Simon J Cook
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

Review 5.  New insights into the biogenesis of nuclear RNA polymerases?

Authors:  Philippe Cloutier; Benoit Coulombe
Journal:  Biochem Cell Biol       Date:  2010-04       Impact factor: 3.626

Review 6.  Modulation of protein kinase signaling cascades by palytoxin.

Authors:  Elizabeth V Wattenberg
Journal:  Toxicon       Date:  2010-11-09       Impact factor: 3.033

Review 7.  The ERK cascade: a prototype of MAPK signaling.

Authors:  Hadara Rubinfeld; Rony Seger
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

8.  MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src.

Authors:  Weiyong Sun; Xudong Wei; Kamala Kesavan; Timothy P Garrington; Ruihua Fan; Junjie Mei; Steven M Anderson; Erwin W Gelfand; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure.

Authors:  Masaaki Hayashi; Sung-Woo Kim; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; E Dale Abel; Brian Eliceiri; Young Yang; Richard J Ulevitch; Jiing-Dwan Lee
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  IFN-γ-inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5.

Authors:  Diana Saleiro; Gavin T Blyth; Ewa M Kosciuczuk; Patrick A Ozark; Beata Majchrzak-Kita; Ahmet D Arslan; Mariafausta Fischietti; Neha K Reddy; Curt M Horvath; Roger J Davis; Eleanor N Fish; Leonidas C Platanias
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.